C4 Therapeutics, Inc. (CCCC) compared with its closest peers (EIKN, PRME, ZURA, RGNX, ARTV). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $615.86M | — |
| Prime Medicine, Inc. (PRME) | $610.49M | -2.6 |
| Zura Bio Limited (ZURA) | $554.79M | -4.9 |
| REGENXBIO Inc. (RGNX) | $553.42M | -3.8 |
| Artiva Biotherapeutics, Inc. (ARTV) | $534.37M | -1.2 |
| Cabaletta Bio, Inc. (CABA) | $530.68M | -1.0 |
| Kyverna Therapeutics, Inc. (KYTX) | $519.48M | -2.6 |
| Editas Medicine, Inc. (EDIT) | $476.10M | -1.1 |
| Ocugen, Inc. (OCGN) | $474.75M | — |
| Ginkgo Bioworks Holdings, Inc. (DNA) | $455.98M | -1.5 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
CCCC overview · CCCC earnings · CCCC financials · CCCC KPIs · CCCC investor relations · CCCC ownership · CCCC filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.